Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: No Labels Clear all
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

NCT02617758
View directory record Official record
Conditions
Healthy
Interventions
Fentanyl
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

NCT03822468
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Anastrozole, Letrozole, Goserelin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
14
States / cities
Mobile, Alabama • Greenbrae, California • Longmont, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05832931
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
49
States / cities
Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Not applicable Interventional Results available

Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

NCT06179290
View directory record Official record
Conditions
Tobacco Use
Interventions
Ploom HTP Menthol HTS; MX3 (681), Ploom HTP Tobacco HTS; R8 (120), Smoking Abstinence (menthol), Smoking Abstinence (non-menthol)
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Bentonville, Arkansas • Rogers, Arkansas • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Bremelanotide, Placebo
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 2, 2026, 1:42 AM EDT
Recruiting Phase 4 Interventional

Single Shot Exparel vs Catheters in Lower Extremity Trauma

NCT07221019
View directory record Official record
Conditions
Fracture Dislocation of Ankle Joint, Fracture Leg, Fracture Femur, Fracture Lower Leg, Fracture
Interventions
Bupivacaine, Exparel + Bupivacaine
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

NCT01801475
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

NCT00130169
View directory record Official record
Conditions
Cancer, Malignant Tumors
Interventions
E7974
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Las Vegas, Nevada • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

NCT03380429
View directory record Official record
Conditions
Asthma
Interventions
RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 2, 2026, 1:42 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT07541170
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Divarasib, Pembrolizumab, Nivolumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Clovis, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sugar Sweetened Beverage Labeling Support

NCT02947802
View directory record Official record
Conditions
Consumer Behavior
Interventions
Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages, Control condition
Other
Lead sponsor
Harvard University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 3 Interventional Results available

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

NCT00348283
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2011 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Carbon-13 (13C)-Spirulina Platensis Gastric Emptying Breath Test (GEBT)

NCT01248221
View directory record Official record
Conditions
Dyspepsia
Interventions
[13C]-Spirulina platensis and 99mTc sulfur colloid
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687
View directory record Official record
Conditions
MPN (Myeloproliferative Neoplasms)
Interventions
Itacitinib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Tempe, Arizona • Orange, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents

NCT04954287
View directory record Official record
Conditions
Covid19
Interventions
CVXGA1 low dose, CVXGA1 high dose
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Bardstown, Kentucky • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 2, 2026, 1:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
Interventions
Capecitabine, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Losartan Potassium, Oxaliplatin, Radiation Therapy, Resection, Diagnostic Imaging, Biospecimen Collection, Gemcitabine, Nab paclitaxel
Drug · Radiation · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 2, 2026, 1:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD

NCT03784963
View directory record Official record
Conditions
Heart Failure, Gastrointestinal Bleeding
Interventions
Omega 3 fatty acids, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Early Phase 1 Interventional

A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

NCT05935891
View directory record Official record
Conditions
Musculoskeletal Syndrome
Interventions
CBD-dominant, THC dominant
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 2, 2026, 1:42 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 1 Interventional

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma

NCT03159117
View directory record Official record
Conditions
Melanoma
Interventions
PF-06688992
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 2, 2026, 1:42 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease

NCT02060526
View directory record Official record
Conditions
Sanfilippo Syndrome
Interventions
Recombinant human heparan N-sulfatase [rhHNS]
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Months to 48 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Torrance, California • Minneapolis, Minnesota • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 2, 2026, 1:42 AM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 2, 2026, 1:42 AM EDT